Kelly Rauber
Ufficiale delle Risorse Umane presso VERA THERAPEUTICS, INC.
Posizioni attive di Kelly Rauber
Società | Posizione | Inizio | Fine |
---|---|---|---|
VERA THERAPEUTICS, INC. | Ufficiale delle Risorse Umane | 01/10/2022 | - |
Storia della carriera di Kelly Rauber
Precedenti posizioni note di Kelly Rauber
Società | Posizione | Inizio | Fine |
---|---|---|---|
DERMIRA, INC. | Ufficiale delle Risorse Umane | - | - |
ORCHARD THERAPEUTICS PLC | Ufficiale delle Risorse Umane | - | - |
ORIC PHARMACEUTICALS, INC. | Ufficiale delle Risorse Umane | - | - |
Formazione di Kelly Rauber
Santa Clara University | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 5 |
Regno Unito | 2 |
Posizioni
Human Resources Officer | 4 |
Undergraduate Degree | 1 |
Settori
Health Technology | 5 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
ORIC PHARMACEUTICALS, INC. | Health Technology |
VERA THERAPEUTICS, INC. | Health Technology |
Aziende private | 2 |
---|---|
Dermira, Inc.
Dermira, Inc. Pharmaceuticals: MajorHealth Technology Dermira, Inc. is a biopharmaceutical company. It engages in the provision of therapies for chronic skin conditions. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Indianapolis, IN. | Health Technology |
Orchard Therapeutics Plc
Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Kelly Rauber
- Esperienza